Stockreport

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapyPositive ProSense® results were reported through 33 peer-r [Read more]